Stockscreener 앱 받기
28.42
1.17%
0.33
시간 외 거래:
28.42
Kiniksa Pharmaceuticals International Plc 주식(KNSA)의 최신 뉴스
Rice Hall James & Associates LLC Sells 18,207 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Shares Bought by GAMMA Investing LLC - Defense World
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - Defense World
KNSA: Analyst Maintains Overweight Rating, Raises Price Target | - GuruFocus
Allspring Global Investments Holdings LLC Trims Holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - Defense World
Wealth Enhancement Advisory Services LLC Purchases New Shares in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - Defense World
Kiniksa Pharmaceuticals: A 7.9 Score and Room for Growth - AOL.com
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Peregrine Capital Management LLC Purchases 65,147 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - MarketBeat
Asset Management One Co. Ltd. Makes New $41,000 Investment in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - Defense World
AMI Asset Management Corp Has $1.73 Million Position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) COO Eben Tessari Sells 17,300 Shares - MarketBeat
Kiniksa pharma COO Tessari sells $489k in shares By Investing.com - Investing.com India
Kiniksa Pharmaceuticals: Arcalyst Performs, KPL-387 Advancing Fast (NASDAQ:KNSA) - Seeking Alpha
Lewis & Ellis acquires Huggins Actuarial Services - Yahoo
UK court rules insurers must pay more than $1bn for planes seized in Russia - Yahoo
Payment software firm Payrails raises $32m in funding - Yahoo
WRAP EU leads textiles extended producer responsibility talks - Yahoo
Canary raises $80m to fuel expansion in hospitality AI - Yahoo
FirmaPak expands global footprint with Lighthouse Packaging acquisition - Yahoo
FDA approves label expansion of AbbVie hepatitis C therapy - Yahoo
Israel attacks Iran, stock market futures tumble - Yahoo
Green Bay Packaging Executive Vice President Bryan Hollenbach to retire in August - Yahoo
Jio BlackRock gets nod to operate as investment adviser in India - Yahoo
Output of key food commodities “on course for new records” – FAO - Yahoo
Why Oklo Stock Dropped on Thursday - Yahoo
Medtech leaders unite on Capitol Hill to fight tariffs - Yahoo
Actabl launches new ProfitSword digital night audit feature for hotels - Yahoo
UCC Holding and Ashghal launch 3D Printed Schools Project in Qatar - Yahoo
Grant Thornton Advisors appoints new COO - Yahoo
Biggby Coffee unveils first brand refresh - Yahoo
Prime Drink Group’s bottling unit enters receivership - Yahoo
Del Taco expands to Louisville with new franchise agreement - Yahoo
Trump’s Treasury Sec Admits It’s Another TACO Day With China - Yahoo
Hakkers and Paebbl introduce carbon-storing solution at Port of Rotterdam - Yahoo
Mistral unveils Europe’s first AI reasoning model Magistral - Yahoo
Costco Announces Important Change for Certain Members Starting June 30 - Yahoo
Transcript : Kiniksa Pharmaceuticals International, plc Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 08 - MarketScreener
MSD receives FDA approval for Enflonsia to prevent RSV - Yahoo
Kiniksa Pharmaceuticals Executives Sell Shares - TradingView
KNSA stock soars to 52-week high, hits $29.71 amid robust gains - Investing.com UK
Kiniksa sets Phase 2/3 trial for heart drug KPL-387 - Investing.com Nigeria
Kiniksa (KNSA) to Launch Phase 2/3 Trial for KPL-387 in 2025 | K - GuruFocus
Kiniksa Pharmaceuticals Announces Trial Design Of Planned Phase 2/3 Clinical Trial Of Kpl-387 In Recurrent Pericarditis - marketscreener.com
Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis | KNSA Stock News - GuruFocus
Kiniksa (KNSA) to Launch Phase 2/3 Trial for KPL-387 in 2025 | KNSA Stock News - GuruFocus
Kiniksa Pharmaceuticals Announces Trial Design of Planned - GlobeNewswire
Kiniksa Advances Revolutionary Monthly Dosing Treatment for Recurrent Pericarditis: Phase 2/3 Trial Details Released - Stock Titan
Louis Vuitton files lawsuit against Portuguese liqueur start-up over branding rights - Yahoo
Kiniksa Pharmaceuticals Annual Shareholders Meeting Decisions - TipRanks
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences - GlobeNewswire
Kiniksa Pharmaceuticals to Present at Jefferies and Goldman Sachs Healthcare Conferences in June - Stock Titan
Kiniksa Pharmaceuticals International PLC (KNSA) Trading 4.13% H - GuruFocus
Kiniksa Pharmaceuticals International PLC (KNSA) Trading 4.13% Higher on May 28 - GuruFocus
Beloved Fast Food Chain Makes Telling Move After Closing Hundreds of Locations - Yahoo
Okika Devices relocates HQ to Colorado Springs - Yahoo
Maryland loses Triple-A bond rating - Yahoo
Dimensional Fund Advisors LP Acquires 29,300 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) - MarketBeat
Kiniksa Pharmaceuticals CEO sells shares worth $218,866 By Investing.com - Investing.com Nigeria
Kiniksa Pharmaceuticals CEO sells shares worth $218,866 - Investing.com Australia
Capra Bank recognized as fastest growing in recent study - Yahoo
Kiniksa Pharmaceuticals: Making Steady Progress (NASDAQ:KNSA) - Seeking Alpha
Insider’s View: Deciphering Kiniksa Pharmaceuticals International Plc (KNSA)’s Financial Health Through Ratios - DWinneX
How should investors view Kiniksa Pharmaceuticals International Plc (KNSA)? - uspostnews.com
8.43%
1.68%
자본화:
|
볼륨(24시간):